This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


  • 00
  • 00
  • 00
  • 00
Delivered as a Hybrid Event from December 12 - 16, 2021
Live In-Person Experience Delivered December 12 - 16 2021Marriott Marquis San Diego

Allan Lawrie, Ph.D.
Professor of Translational Cardiopulmonary Science at University of Sheffield Medical School


Allan Lawrie is a Professor of Translational Cardiopulmonary Science and British Heart Foundation Senior Basic Science Research Fellow in the Department of Infection, Immunity & Cardiovascular Disease at the University of Sheffield. Allan’s research has focused on identifying a key role for osteoprotegerin/TRAIL pathway in the pathogenesis of PAH. Supported by Fellowships and grants from the MRC and BHF he has recently developed a novel human therapeutic antibody targeting this pathway. Allan also works closely with clinical colleagues locally, nationally and internationally to identify biomarkers and utilise multi-omic approaches for molecular phenotyping, identifying novel disease mechanisms and drug targets.

Agenda Sessions

  • A Novel Therapeutic Antibody Targeting Human Osteoprotegerin Attenuates Severe Experimental Pulmonary Arterial Hypertension

    On Demand
  • Novel Non-cancer Targets for Therapeutic Antibodies